Cargando…
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
ASXL1 is the obligate regulatory subunit of a deubiquitinase complex whose catalytic subunit is BAP1. Heterozygous mutations of ASXL1 that result in premature truncations are frequent in myeloid leukemias and Bohring–Opitz syndrome. Here we demonstrate that ASXL1 truncations confer enhanced activity...
Autores principales: | Balasubramani, Anand, Larjo, Antti, Bassein, Jed A., Chang, Xing, Hastie, Ryan B., Togher, Susan M., Lähdesmäki, Harri, Rao, Anjana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Pub. Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557297/ https://www.ncbi.nlm.nih.gov/pubmed/26095772 http://dx.doi.org/10.1038/ncomms8307 |
Ejemplares similares
-
Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
por: Xia, Yu-Kun, et al.
Publicado: (2020) -
Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
por: Asada, Shuhei, et al.
Publicado: (2018) -
Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1
por: Daou, Salima, et al.
Publicado: (2018) -
BAP1/ASXL1 recruitment and activation for H2A deubiquitination
por: Sahtoe, Danny D., et al.
Publicado: (2016) -
ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)